Arcus Biosciences and partner Gilead halted Phase III work on their anti‑TIGIT antibody domvanalimab after independent data monitoring committees flagged futility in upper gastrointestinal cancers, prompting Arcus to cancel several trials and redirect R&D resources. The companies reported that combining domvanalimab with an anti‑PD‑1 and chemotherapy failed to meet interim efficacy thresholds in gastric and esophageal indications. Arcus said it will shift effort away from domvanalimab and reallocate capital toward other discovery and development programs; Gilead’s role in the partnership and next steps for the asset were described in company statements. An earlier independent recommendation to stop one study underlined mounting skepticism about TIGIT as a broadly applicable checkpoint target following other industry setbacks. Investors and partners are watching how Arcus repositions its pipeline and whether the companies will pursue biomarker‑guided niches for TIGIT or abandon the target entirely. The decisions also influence broader oncology portfolios that had prioritized TIGIT combinations.